I need to quote a good bit, because it is so shocking (the bolding is mine):
"During his videotaped deposition in October 2016, [Aetna medical director] Iinuma – who signed the pre-authorization denial – said he never read Washington’s medical records and knew next to nothing about his disorder. Intravenous immunoglobulin can cost as much as $20,000 per treatment. It helps patients like Gillen Washington stave off infection. Questioned about Washington’s condition, Iinuma said he wasn’t sure what the drug of choice would be for people who suffer from his condition.
Iinuma further says he’s not sure what the symptoms are for the disorder or what might happen if treatment is suddenly stopped for a patient. “Do I know what happens?” the doctor said. “Again, I’m not sure. … I don’t treat it.”
Iinuma said he never looked at a patient’s medical records while at Aetna. He says that was Aetna protocol and that he based his decision off “pertinent information” provided to him by a nurse. “Did you ever look at medical records?” Scott Glovsky, Washington’s attorney, asked Iinuma in the deposition.
"No, I did not," the doctor says, shaking his head.'
“So as part of your custom and practice in making decisions, you would rely on what the nurse had prepared for you?” Glovsky asks.
“Correct.”
Iinuma said nearly all of his work was conducted online. Once in a while, he said, he might place a phone call to the nurse for more details. How many times might he call a nurse over the course of a month?
“Zero to one,” he said. […]
“Oh my God. Are you serious? That is incredible,” said Dr. Anne-Marie Irani […] a professor of pediatrics and internal medicine at the Children’s Hospital of Richmond at VCU and a former member of the American Board of Allergy and Immunology’s board of directors.
“This is potentially a huge, huge story and quite frankly may reshape how insurance functions,” said Dr. Andrew Murphy, who, like Irani, is a renowned fellow of the American Academy of Allergy, Asthma and Immunology. He recently served on the academy’s board of directors."
The excerpt is taken from:
You can also find the report on Forbes and Fortune: